Longeveron Inc.

News & Events

Press Releases

In The Media

1. Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease

   GlobeNewswire JUL 21, 2025 9:15 AM EDT
   Longeveron has licensed issued US Patent 12,168,028 B2 , entitled “Methods for obt...
   READ ARTICLE

2. Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM)

   GlobeNewswire JUL 8, 2025 9:15 AM EDT
   Accepted IND application allows for development program to move directly to a Phase 2 pivotal reg...
   READ ARTICLE

3. Longeveron® Appoints Than Powell as Chief Business Officer

   GlobeNewswire JUN 26, 2025 9:05 AM EDT
   Mr. Powell to oversee Longeveron’s partnering and international strategy efforts ...
   READ ARTICLE

4. Longeveron® Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS)

   GlobeNewswire JUN 24, 2025 6:30 AM EDT
   Top-line trial results are anticipated in the third quarter of 2026, after the final follow-up at...
   READ ARTICLE

5. Longeveron® to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

   GlobeNewswire JUN 9, 2025 9:15 AM EDT
   MIAMI, June 09, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage reg...
   READ ARTICLE

6. Longeveron® to Attend BIO International Convention 2025

   GlobeNewswire MAY 20, 2025 9:15 AM EDT
   Focus on potential partnership and strategic opportunities for the Company’s stem cell the...
   READ ARTICLE

7. Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient

   GlobeNewswire MAY 12, 2025 7:15 AM EDT
   Longeveron selected as a Top 40 Semifinalist based on the feasibility of its stem cell therapy ...
   READ ARTICLE

8. Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update

   GlobeNewswire MAY 8, 2025 4:05 PM EDT
   Pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel in HLHS, a rare pediatric dis...
   READ ARTICLE

9. Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

   GlobeNewswire MAY 2, 2025 8:30 AM EDT
   MIAMI, May 02, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage rege...
   READ ARTICLE

10. Longeveron® Issues Letter to Shareholders Highlighting Corporate Strategy, Recent Progress and Key Priorities and Goals for 2025

    GlobeNewswire APR 22, 2025 4:05 PM EDT
    MIAMI, April 22, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage re...
    READ ARTICLE